Colin Broom
DirectorDr. Colin Broom, M.D., has served as Chief Executive Officer of Pulmotect, Inc. since September 2019 and serves as its Director. Dr. Broom served as the Chief Executive Officer of Nabriva Therapeutics Plc from April 12, 2017 to July 24, 2018 and its Interim Chief Medical Officer from September 30, 2017 to March 2018. Dr. Broom was previously Chief Executive Officer of Nabriva Therapeutics plc from April 12, 2017 until July 24, 2018, and the Chief Executive Officer of Nabriva Austria from August 2014 until the Redomiciliation. At Nabriva he was responsible for developing the recently approved drug Xenleta (lefamulin) and taking it public in 2015. Dr. Broom served as Member of Management Board of Nabriva Therapeutics Plc since August 28, 2014. Dr. Broom has been the Chief Executive Officer and Member of Management Board at Nabriva Therapeutics GmbH since August 28, 2014. He served as the Chief Scientific Officer and Vice President of ViroPharma Inc. from May 2004 to January 24, 2014. Dr. Broom was responsible for the leadership of all product development activities and plays a key role in ViroPharma Inc.'s strategic business development efforts. He served as Vice President of Clinical Development and Medical Affairs Amgen Inc. from 2000 to 2003. Prior to this, he served as Senior Vice President of Global Clinical Development for Hoechst Marion Roussel (now Aventis) and Vice President, Clinical Development, North America at SmithKline Beecham (now GlaxoSmithKline). Dr. Broom led Amgen's European drug development activities and built a medical affairs capability to take full advantage of the outstanding regulatory successes attained during his tenure, which included approvals for Aranesp(r) (darbepoetin alfa) nephrology and oncology indications, Neulasta(r) (pegfilgrastim) for chemotherapy induced neutropenia and Kineret(r) (anakinra) for rheumatoid arthritis. He has worked in biopharmaceutical drug development and commercialization for many years. Dr. Broom has pharmaceutical industry experience. Prior to joining Amgen, he served as the Senior Vice President of Global Clinical Development for Hoechst Marion Roussel (HMR), where he had global responsibility for clinical development strategy across all therapeutic areas. Prior to HMR, he held positions of increasing seniority at Glaxo and SmithKline Beecham (SB) in clinical pharmacology before moving to the U.S. with SB to lead the global oncology therapeutic area and subsequently the CNS and GI areas. At HMR and SB, he led or made major contributions to the development programs, regulatory approvals and commercialization of products across multiple therapeutic areas including Lantus(r) (insulin glargine) for diabetes, Hycamtin(r) (topotecan) in oncology, Paxil(r) (paroxetine) and Requip(r) (ropinirole) for CNS disorders, Kytril(r) (granisetron) for nausea and vomiting associated with chemotherapy and Famvir(r) (famciclovir) anti-viral therapy. He has been a Director of Nabriva Therapeutics plc since June 23, 2017. He served as a Director of NPS Pharmaceuticals, Inc. from July 2009 to February 21, 2015. Among other affiliations, Dr. Broom is a Member of the American Society of Clinical Pharmacology and Therapeutics, the British Pharmacological Society and the British Society of Gastroenterology. He is a Member of the U.K. Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians. Dr. Broom holds a Bachelor of Science Degree in Pharmacology from University College London and a Bachelor of Medicine and Bachelor of Surgery Degree from St. George's Hospital Medical School, London. He served as a Member of Advisory Board at Kinderpharm LLC.
Positions
- Company NameNabriva Therapeutics plcStock CodeNBRVFPositionDirector
